Uncategorized

COVID-19–Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status — COVID-NET, 14 States, July 2021–January 2022 | Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital Complications | SARS-CoV-2 Placentitis and Intraparenchymal Thrombohematomas Among COVID-19 Infections in Pregnancy | De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Children and COVID19: State Level Data Report | Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022 | Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 | High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron | Comparison of Seroconversion in Children and Adults With Mild COVID-19

SARS-CoV-2 is associated with changes in brain structure | New Onset Dementia Among Survivors of Pneumonia Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Whole genome sequencing reveals host factors underlying critical Covid-19 | Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality | Pfizer Initiated a Phase 2/3 Study of their Novel COVID-19 Oral Treatment in Pediatric Participants | Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID | Development and validation of SCOPE score: a clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure | Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant | Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network

Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19, 14 States, July 2021–January 2022 | SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract | Direct Observation of Repeated Infections With Endemic Coronaviruses | Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model | o Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2 | Sanofi and GSK will seek regulatory authorization for their COVID-19 vaccine

Children and COVID19: State Level Data Report | Placental Tissue Destruction and Insufficiency from COVID-19 Causes Stillbirth and Neonatal Death from Hypoxic-Ischemic Injury: A Study of 68 Cases with SARS-CoV-2 Placentitis from 12 Countries | Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report | Azithromycin in patients with COVID-19: a systematic review and meta-analysis | Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Children and COVID19: State Level Data Report
| Safety, tolerability and viral kinetics during SARS-CoV-2 viral challenge
| Long-term cardiovascular outcomes of COVID-19 | FDA to discuss request authorization for the Pfizer COVID-19 Vaccine for use in children 6 months-4 years | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron | Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Children and COVID19: State Level Data Report | Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant | Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study | U.S. FDA approves the Moderna COVID-19 Vaccine (Spikevax) for the prevention of COVID-19 in individuals 18 years of age and older | Novavax Submitted a Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C | Viral Interference between Respiratory Viruses | Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–